PURPOSE Clopidogrel is a prodrug that requires transformation into an active metabolite by cytochrome P450 (CYP) in the liver in order to irreversibly inhibit the P2Y12 adenosine diphosphate platelet receptor. CYP2C19 polymorphism has been reported to correlate with reduced antiplatelet activity of clopidogrel in coronary artery disease. We assessed the association between CYP2C19 polymorphism ...

Although many cases of interindividual variation in the metabolism of CYP2C19 drugs are explained by the CYP2C19*2, *3, and *17, a wide range of metabolic variation still occurs in people who do not carry these genetic variants. The objectives of this study were to identify new genetic variants and to characterize functional consequences of these variants in metabolism of CYP2C19 substrates. In...

BACKGROUND Previous studies accessing the association of CYP2C19 with outcomes of patients using tamoxifen for breast cancer have yielded conflicting results. The aim of this meta-analysis is to obtain a more precise estimate of effects of CYP2C19 polymorphisms and to clarify their effects on survival of the breast cancer patients using tamoxifen. MATERIALS AND METHODS A systematic search of ...

Ticagrelor is a reversibly binding P2Y12 receptor antagonist that has undergone phase 3 clinical trials and is currently under Food and Drug Administration (FDA) review. Ticagrelor has proposed benefits over clopidogrel in that it has a faster onset of action, greater platelet inhibitory potency, and less interpatient variability in pharmacodynamic response. Unlike clopidogrel, ticagrelor does ...

Inter-individual pharmacokinetic variation of H(2)-receptor antagonist is related to genetic polymorphism of CYP2C19. We investigated the frequency of CYP2C19 genetic polymorphism and the treatment duration of cimetidine by CYP2C19 genotypes in functional dyspeptic patients without definite causes who were treated with cimetidine in Korea. One hundred subjects with functional dyspepsia particip...

Coronary Heart Disease (CHD) is a cardiovascular disease that can caused by the presence of coronary artery plaque blockage. Clopidogrel one antiplatelet therapy in CHD patients. CYP2C19 *2 polymorphisms reduce effectiveness clopidogrel active metabolites. This research was conducted at RSUD Sidoarjo East Java from November to December 2017continued monitoring events March 2018. The method used...

nomics 2008;9:691–702. 168. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol 2007;34:102–105. 169. Lamba JK, Dhiman RK, Kohli KK. Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects. Clin Pharmacol Ther 1998;63:422–427. 170. Adithan C, Gerard N, Vasu ...

BACKGROUND Categorization as a cytochrome P450 (CYP) 2C19 poor metabolizer (PM) is reported to be an independent risk factor for cardiovascular disease. Epoxyeicosatrienoic acids (EETs) are metabolites of arachidonic acid by CYP2C19 epoxygenases and anti-inflammatory properties, especially in microvascular tissues. We examined the impact of CYP2C19 polymorphisms and EETs on the patients with mi...

OBJECTIVE To evaluate the contribution of six polymorphisms to the platelet reactivity in patients with acute coronary syndrome (ACS) treated with clopidogrel. METHODS Cross-sectional study of 278 consecutive patients with ACS. Detailed clinical information for each patient was collected and genotypes (CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*17, CYP3A4*1B, and PON1-Q192R) were evaluated with T...